The ligand-binding properties of the gastrin-releasing peptide (GRP) receptor and the cellular processing of GRP have been studied in the small-cell lung cancer (SCLC) cell line COR-L42. Scatchard analysis of GRP receptor expression indicated a single class of high-affinity receptors (Kd 1.5 nM) and approx. 6700 receptors/cell. GRP bound to its receptor with a K1 of 2.4 nm. The bombesin-related peptides neuromedin B (NMB) and phyllolitorin also bound to GRP receptors with K, values of 22.7 and 59.1 nm respectively. Binding of 125I-GRP to COR-L42 cells increased rapidly at 37°C, achieved a maximum at 10 min and declined rapidly thereafter. At 4°C, maximum binding was achieved at 30 min and the subsequent decline in cell-associated radioactivity was slower than that seen at 37 'C. Acid/salt extraction, to separate surface-bound ligand from internalized GRP, indicated that after receptor binding 125I-GRP was rapidly internalized. To determine the pathway of 125I-GRP degradation, binding studies were carried out with the lysosomotropic agent chloroquine (5 mM), and with phosphoramidon (10,UM), an inhibitor of the membrane-bound enzyme (EC 3.4.24.11).
INTRODUCTION
Amphibian bombesin-like peptides are a family of structurally related peptides (Nakajima et al., 1970; Anastasi et al., 1971; Yasuhara et al., 1983; Barra et al., 1985) comprising the bombesin, ranatensin and phyllolitorin subfamilies. Only bombesin-and ranatensin-like peptides have mammalian counterparts, namely gastrin-releasing peptide (GRP) and neuromedin B (NMB) respectively (McDonald et al., 1978; Minamino et al., 1983 Minamino et al., , 1985 . GRP is a potent mitogen for Swiss 3T3 cells (Rozengurt & Sinnett-Smith, 1983; Zachary & Rozengurt, 1985) and also has been shown to be an autocrine growth factor for small-cell lung cancer (SCLC) . SCLC cells synthesize (Moody et al., 1981) and secrete (Korman et al., 1986 ) GRP, express high-affinity GRP receptors Gaudino et al., 1988; Layton et al., 1988; Kado-Fong & Malfroy, 1989) and respond mitogenically to GRP stimulation (Carney et al., 1987) . In addition, they are growth-inhibited by antibodies to GRP, confirming an autocrine function for this peptide in SCLC .
Receptor binding and internalization of GRP in Swiss 3T3 and HIT pancreatic islet cells has been shown to be a rapid process which is followed by ligand internalization (Zachary & Rozengurt, 1987a; Swope & Schonbrunn, 1987; Brown et al., 1988) and lysosomal degradation (Westendorf & Schonbrunn, 1983; Zachary & Rozengurt, 1987a; Swope & Schonbrunn, 1987; Brown et al., 1988) . Unlike the receptors for several growth factors (Carpenter & Cohen, 1976; Heldin et al., 1982; Moscatelli, 1988; Galizzi et al., 1989; Samanta et al., 1990) , GRP receptors appear not to undergo down-regulation in Swiss 3T3 cells (Zachary & Rozengurt, 1987a; Brown et al., 1988) . This observation raises the possibility that extensive receptor downregulation is not in every case an obligatory event for the initiation of cell proliferation. In contrast, GRP receptor downregulation has been demonstrated in the HIT pancreatic islet cell line following the addition of 100 nM-GRP for 90 min at 37°C (Swope & Schonbrunn, 1987) . These observations indicate differences in GRP receptor regulation in different cell types.
Although it has been shown that '25I-GRP binds to specific cell surface receptors on SCLC cell lines Gaudino et al., 1988; Layton et al., 1988; Kado-Fong & Malfroy, 1989) and stimulates rapid and transient mobilization of Ca21 (Heikkila et al., 1987; Woll & Rozengurt, 1989; Bunn et al., 1990) , little is known about the cellular processing of GRP and its receptor in these cells. Given the acknowledged role of GRP as an autocrine growth factor for SCLC and its potential as a target for novel anti-cancer therapies, the present study investigates GRP receptor bindig and internalization, GRP catabolic pathways and GRP receptor down-regulation in the recently-derived SCLC cell line COR-L42.
MATERIALS AND METHODS

Materials
125I-GRP (2000 Ci/mmol) was purchased from Amersham. GRP (pig) was obtained from Cambridge Research Biochemicals, Cambridge, U.K., and phyllolitorin and [Lys3]bombesin were from Peninsula Laboratories Europe, Ltd., St. Helens, Merseyside, U.K. Sodium selenite, transferrin, insulin, Bes, aprotinin, phosphoramidon, chloroquine, cycloheximide, GRP (human), , ranatensin, litorin, alytesin, NMB and substance P were all obtained from Sigma Chemical Co.
Cell line
The derivation and characterization of the SCLC COR-L42 cell line has been described elsewhere (Baillie-Johnson et al., 1985) . Briefly, this cell line shows a deletion in the short arm of chromosome 3 (Ibson et al., 1987) , contains high levels of neuron-specific enolase and creatinine kinase BB, a low level of L-dopa decarboxylase activity (Baillie-Johnson et al., 1985) , and does not express the GRP gene (Cardona et al., 1991) . These properties are consistent with its classification as a variant SCLC (SCLC-V) cell line . Cells were grown routinely in RPMI-1640 medium supplemented with 10 % foetal calf serum, 2 mM-L-glutamine, 100 ,ug of penicillin/ml and 100 ,ug of streptomycin/ml (all from Gibco Ltd.).
Time course of '25l-GRP binding COR-L42 cells were harvested by centrifugation. Cells were then rinsed in RPMI-1640 medium supplemented with sodium selenite (30 nM), insulin (50 /tg/ml) and transferrin (100 mg/ml) (RPMI/SIT medium) and resuspended in the same medium containing 0.25 % BSA, 50 mM-Bes and aprotinin (100 kallikreininhibiting units/ml) at pH 6.5 (binding buffer). Cells were monodispersed by gentle syringing, transferred to silicone-coated Eppendorf tubes (4 x 106 cells/tube), and 0.5 nM-125I-GRP was added in the presence or absence of 1 /tM unlabelled GRP. The total volume was 200,tl and each assay was performed in duplicate. Cells were rapidly washed after various incubation times with ice-cold washing solution containing 0.15 M-NaCl, 0.02 M-NaH2PO4, 5 mM-KCl, 1.8 mM-KH2PO4, 5 mm-MgCl2 and 0.25 % BSA, pH 6.7 (washing buffer). Cell-associated radioactivity was determined in a y-radiation counter (Compugamma CS; LKB Wallace). Non-specific binding is defined as the cellassociated radioactivity not displaced in the presence of excess GRP (1 ezM). Specific binding was calculated by subtracting the non-specific binding from the total cell-associated radioactivity.
Specificity of GRP receptors
Competition for GRP-binding sites was studied by incubating cells in the presence of 0.5 nM-1251I-GRP and 0.1-10 000 nm unlabelled peptides. After 10 min at 37°C the cells were rapidly washed in ice-cold washing buffer and cell-associated radioactivity was determined.
Cellular distribution of 125I-GRP Surface-bound and internalized ligand were separated using an acid/salt extraction procedure previously used to dissociate GRP from GRP receptors expressed on Swiss 3T3 cells (Zachary & Rosengurt, 1987a) , based on the method of Haigler et al. (1980) . Briefly, after various incubation times in the presence of 0.5 nM-1251-GRP at either 4°C or 37°C, cells were washed rapidly three times with ice-cold washing buffer and then treated for 6 min with 1 ml of 0.2 M-acetic acid/0.5 M-NaCl, pH 2.5, at 4 'C. Cells were centrifuged at 13 400 g for 10 s and were washed once with 0.5 ml of phosphate-buffered saline. Washings and cell pellets were counted for radioactivity in a y-radiation counter to determine both the surface-bound cell-associated radioactivity and the intracellular cell-associated radioactivity.
Determination of '251-GRP degradation
To determine the optimum concentrations of chloroquine and phosphoramidon to inhibit degradation of GRP, cells were incubated with 0.5 nM-125I-GRP in the presence of 5-5000 4uM-chloroquine or 10-10000 nM-phosphoramidon for 30 min. Cells were washed in ice-cold buffer and cell-associated radioactivity was determined. Control cultures received no inhibitor pretreatment and were incubated with 0.5 nM-125I-GRP only. In subsequent studies, cells were incubated in the absence or the presence of S mM-chloroquine and/or 10 4uM-phosphoramidon. Cells were washed and counted for radioactivity as previously described. Cell viability, as determined by Trypan Blue exclusion, was not affected by these agents.
Effect of pretreatment with unlabelled GRP, cycloheximide and chloroquine on the subsequent binding of 1251-GRP Cells were pretreated in the presence of 5 mM-chloroquine at 37 'C for 30 min. These and parallel untreated control cells were then incubated with 100 nM-GRP in the presence or the absence of 10, tg of cycloheximide/ml or 5 mM-chloroquine at 37 'C. After various incubation times, cells were washed twice with binding buffer at 4 'C and incubated in fresh binding buffer with 0.5 nM-'25I-GRP at 37 'C for 10 min. Cells were then washed and counted for radioactivity as previously described. Cell viability, as determined by Trypan Blue exclusion, was not affected by the action of these agents.
Effect of pretreatment with various unlabelled peptides on the subsequent binding of 1251-GRP In order to examine the ability of unlabelled peptides to downregulate GRP receptors, cells were incubated either in the presence or in the absence of alytesin (100 nM), NMB (100 nM), phyllolitorin (100 nM) or substance P (1 #M). and pig GRP, ranatensin, litorin, NMB and phyllolitorin competed with 125I-GRP for GRP-binding sites on COR-L42 cells in a concentration-dependent manner. Substance P and GRP-(1-16), the N-terminal amino acid sequence of GRP which is known to have no receptor-binding properties (Zachary & Rozengurt, 1987b) , failed to compete for GRP-binding sites. Table 1 shows that for human GRP the concentration of unlabelled peptide required to inhibit 50 % of the specific binding Binding and cellular distribution of 1251-GRP Fig. 3(a) shows the time course of 1251-GRP binding at 37°C and 4°C in COR-L42 cells. Maximum binding was achieved after 10 min at 37°C, followed by a decline in cell-associated radioactivity at longer incubation times. At 4°C maximum binding was achieved after 30 min, and the decline in specific binding at longer incubation times was markedly slower than that seen at 37 'C.
To investigate GRP receptor internalization, surface-bound and internalized ligand were separated using an acid/salt extraction procedure. Internalized versus surface-bound cell- Fig. 3(b) . Approx. 700% of bound '25I-GRP was internalized after 10 min. Cell-surface and internalized 125I-GRP rapidly declined thereafter. Internalized 125I-GRP remained at approx. 70% of total cell-associated radioactivity throughout the time course. Fig. 3(c) shows that at 4°C approx. 80% of cellassociated radioactivity remained surface-bound throughout the time course.
Degradation of 125I-GRP
To determine the pathway of 125I-GRP degradation, the effects of the lysosomotropic agent chloroquine (5-50000 ,SM) and of phosphoramidon (10-10000 nM) on cell-associated radioactivity were studied. Fig. 4 shows that both chloroquine and phosphoramidon increased total binding of 125I-GRP to COR-L42 cells in a dose-dependent manner. For subsequent experiments 5 mm and 10 puM concentrations of chloroquine and phosphoramidon respectively were used. Effect of exposure to other peptides on the subsequent binding of 1251-GRP A comparison of the subsequent binding of 1251I-GRP to COR-L42 cells following pretreatment with GRP (100 nM), alytesin (100 nM), NMB (100 nM), phyllolitorin (100 nM) or substance P (1 uM) is shown in Table 2 . It can be seen that pretreatment with alytesin significantly decreased the subsequent binding of 125I1 GRP. Pretreatment of cells with NMB, phyllolitorin or substance P failed to influence significantly the subsequent binding of 125I1 GRP.
DISCUSSION
The mechanism by which a cell may be driven into mitogenesis requires the interaction between a growth factor and its receptor to form a ligand-receptor complex (Carpenter & Cohen, 1976; Heldin et al., 1982; Walker & Burgess, 1987; Furlanetto, 1988; Galizzi et al., 1989) . Previous studies have shown that 125I-GRP binds to a single class of high-affinity receptors on SCLC cells Layton et al., 1988; Kado-Fong & Malfroy, 1989) , and stimulates mobilization of intracellular Ca2+ in these cells (Heikkila et al., 1987; Woll & Rozengurt, 1989; Bunn et al., 1990 ). The present study shows that in the SCLC cell line COR-L42, 125I-GRP binds to a single class of high-affinity receptors and is rapidly internalized and subsequently degraded. At 37°C, approx. 75 % of radiolabelled GRP was internalized by COR-L42 cells, this energy-dependent process having a markedly lower rate at 4°C, as indicated by retention of 125I-GRP at the cell surface. These findings suggest that, like other peptide growth factors (Carpenter & Cohen, 1976; Heldin et al., 1982; Walker & Burgess, 1987; Furlanetto, 1988; Galizzi et al., 1989) , GRP is internalized by receptor-mediated endocytosis in COR-L42 cells. Although similar findings have been reported in Swiss 3T3 fibroblasts (Zachary & Rozengurt, 1987a) and HIT (pancreatic islet) cells (Swope & Schonbrunn, 1987) , an earlier study of 125I-[Tyr4lbombesin binding to the SCLC cell line NCI-H446 reported that all binding of [Tyr4]bombesin was reversible and that little if any of the peptide was internalized by these cells . The non-concordance between this finding and those of the present study may reflect differences in the ability of SCLC cell lines to internalize bombesin/GRP, a contention supported by the finding that no decrease in cellassociated radioactivity was observed in NCI-H446 cells after maximum binding had been reached .
Competitive binding studies with bombesin-related peptides indicated that [Lys3]bombesin, alytesin, GRP-10 and GRP (human and pig) potently bound to GRP receptors. Ranatensinlike peptides also competed with '25I-GRP, but less potently than the bombesin peptides. This finding is particularly noteworthy, given that lung tumour cell lines have been shown recently to express the NMB gene and to synthesize this peptide (Cardona et al., 1991) . Since NMB is a mitogen for SCLC (Bepler et al., 1988) , NMB may function as an autocrine growth factor in SCLC cells exerting its effects at least in part through interaction with GRP receptors. Interestingly, phyllolitorin, the third member of the bombesin-like peptide subfamilies, also bound to GRP receptors with a K1 of 59.1 nm.
After internalization of the ligand-receptor complex and the formation of endosomes, ligands and their receptors are dissociated and segregated (Brown et al., 1983; Geuze et al., 1983; Presky & Schonbrunn, 1986) . Numerous reports have demonstrated degradation of ligands and ligand-receptor complexes by the action of several enzymes (King et al., 1980; Heldin et al., 1982; Walker & Burgress, 1987) . The present study indicates that in COR-L42 cells, 1251I-GRP is degraded by endo/exopeptidases. Chloroquine is a weak base which acts by increasing intralysosomal pH, thus inhibiting further processing of ligand-receptor complexes (Wibo & Poole, 1974; Seglen et al., 1979; Marshall & Olefsky, 1979; Poole & Ohkuma, 1981; Maxfield, 1982) . Binding studies carried out in the presence of chloroquine showed that after 1251-GRP binding and internalization, cell-associated radioactivity did not decline, indicating that the subsequent degradation of I251-GRP was inhibited by this agent. Similarly, phosphoramidon, which is an inhibitor of the EC 3.4.24.11 enzyme responsible for the degradation of GRP (Bunnett et al., 1985) , delayed the decrease in cell-associated radioactivity in COR-L42 cells. These findings indicate that in COR-L42 cells GRP is not only degraded by a lysosomal pathway as previously described for Swiss 3T3 cells (Zachary & Rozengurt, 1987a; Brown et al., 1988) , HIT cells (Swope & Schonbrunn, 1987) and pituitary cells (Westendorf & Schonbrunn, 1983) , but is also degraded by a phosphoramidonsensitive extracellular pathway possibly involving the EC 3.4.24.11 enzyme, recently shown to be the common acute lymphoblastic leukaemia antigen (CALLA) (Shipp et al., 1989) .
Receptor-mediated endocytosis results, in many cases, in a marked decrease in the number of receptors, a phenomenon known as receptor down-regulation. Indeed, it has been shown extensively that binding of growth factors and polypeptides to their receptors often leads to receptor down-regulation (Carpenter & Cohen, 1976; Heldin et al., 1982; Moscatelli, 1988; Galizzi et al., 1989; Samanta et al., 1990) . Furthermore, receptor down-regulation has been implicated in the initiation of mitogenesis (Rozengurt, 1986; Glenney et al., 1988) . In the present study evidence for GRP receptor down-regulation in COR-L42 cells was obtained, in that following GRP pretreatment 1251I-GRP binding was significantly decreased compared with control levels. It is unlikely that this decrease is due to the occupation of GRP receptors by unlabelled GRP, since acid/salt extraction studies indicate that much of the unlabelled GRP would have been internalized during the pretreatment period. Furthermore, both NMB and phyllolitorin are able to bind to GRP receptors and would similarly occupy surface GRP receptors. However, no decrease in the subsequent binding of 1251I-GRP was observed following pretreatment with these peptides. As expected, pretreatment with the amphibian peptide alytesin, which is also a member of the bombesin subfamily and has a C-terminal decapeptide sequence with only a single amino acid difference compared to that of GRP, markedly inhibited the subsequent binding of GRP to its receptor. Interestingly, GRP receptor down-regulation has also been demonstrated in a pancreatic islet cell line (Swope & Schonbrunn, 1987) . In contrast, GRP receptors appear not to be down-regulated in the Swiss 3T3 cell line (Zachary & Rozengurt, 1987a; Brown et al., 1988) . These findings indicate differences in GRP receptor regulation in Swiss 3T3 and SCLC cells. In this context, it is interesting to note that basic fibroblast growth factor receptors appear to be down-regulated in baby hamster kidney cells, in mouse lung capillary endothelial cells and in bovine capillary endothelial cells, but not in Swiss 3T3 cells (Neufeld & Gospodarowicz, 1985; Olwin & Hauschka, 1986; Friesel et al., 1986; Moscatelli, 1988) .
Following internalization and dissociation of the ligandreceptor complex, receptors and ligands can either be inactivated by the action of specific hydrolases or return intact to the cell surface to be re-utilized (Marshall, 1985) . In the present study a substantial recovery in the number of GRP-binding sites was observed following receptor down-regulation. A similar reappearance of down-regulated receptors has been observed for asialoglycoprotein, macroglobulin and low-density lipoprotein receptors (Brown et al., 1983; Berg et al., 1983; Dunn & Hubbard, 1984) , cytokine receptors (Samanta et al., 1990 , Galizzi et al., 1989 Murthy et al., 1989) and calcitonin receptors (Schneider et al., 1988) . Pretreatment of COR-L42 cells with cycloheximide, to inhibit the synthesis ofnew GRP receptors, and with chloroquine, an agent which blocks receptor recycling (Marshall et al., 1981; Knutson et al., 1983) , resulted in a decrease in 125I-GRP binding to 60 % and 30 % respectively of control levels. These findings indicate that although some GRP receptors are synthesized de novo, the majority of GRP receptors are re-utilized.
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